Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR+5.9%
5Y CAGR-3.2%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+5.9%/yr
Quarterly compound
5Y CAGR
-3.2%/yr
Recent acceleration
Percentile
P79
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 24.14% |
| Q3 2025 | -20.18% |
| Q2 2025 | 1.40% |
| Q1 2025 | 4.37% |
| Q4 2024 | 9.57% |
| Q3 2024 | -7.57% |
| Q2 2024 | -3.14% |
| Q1 2024 | 12.90% |
| Q4 2023 | -7.46% |
| Q3 2023 | -0.99% |
| Q2 2023 | 4.64% |
| Q1 2023 | 31.08% |
| Q4 2022 | 20.33% |
| Q3 2022 | 14.95% |
| Q2 2022 | -5.31% |
| Q1 2022 | 0.00% |
| Q4 2021 | 20.21% |
| Q3 2021 | -20.34% |
| Q2 2021 | -2.48% |
| Q1 2021 | -3.34% |
| Q4 2020 | 28.44% |
| Q3 2020 | 20.86% |
| Q2 2020 | -17.67% |
| Q1 2020 | 51.27% |
| Q4 2019 | -25.30% |
| Q3 2019 | -7.16% |
| Q2 2019 | -2.45% |
| Q1 2019 | 68.14% |
| Q4 2018 | 159.21% |
| Q3 2018 | -61.99% |
| Q2 2018 | -19.25% |
| Q1 2018 | 85.77% |
| Q4 2017 | -39.41% |
| Q3 2017 | -14.56% |
| Q2 2017 | -14.30% |
| Q1 2017 | 45.49% |
| Q4 2016 | 13.34% |
| Q3 2016 | -42.98% |
| Q2 2016 | 20.35% |
| Q1 2016 | 39.72% |